Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Clinical Oncology

• Publication date

  2015-04-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2014.58.8848PMID 25779564PMCID PMC4517072
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Homologous recombination-deficient tumors are hyper-dependent on POLQ-mediated repair

  2015cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.

  2015cited by this paper
• 214 Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancer

  2014cited by this paper
• Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

  2014cited by this paper
• Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition

  2014cited by this paper
• The PARP Inhibitors, Veliparib and Olaparib, Are Effective Chemopreventive Agents for Delaying Mammary Tumor Development in BRCA1-deficient Mice

  2014cited by this paper
• Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers

  2014cited by this paper
• PTIP associates with Artemis to dictate DNA repair pathway choice

  2014cited by this paper
• The oligonucleotide/oligosaccharide-binding fold motif is a poly(ADP-ribose)-binding domain that mediates DNA damage response

  2014cited by this paper
• Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

  2014cited by this paper
• Requirement for Parp-1 and DNA ligases 1 or 3 but not of Xrcc1 in chromosomal translocation formation by backup end joining

  2014cited by this paper
• Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer

  2014cited by this paper
• Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

  2014cited by this paper
• PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.

  2014cited by this paper
• PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.

  2014cited by this paper
• Association between metformin use and mortality in patients with prostate cancer: explained by confounding by indication?

  2014cited by this paper
• Molecular Pathways Molecular Pathways : How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors ?

  2014cited by this paper
• 215 Updated clinical and preliminary correlative results of ARIEL2, a Phase 2 study to identify ovarian cancer patients likely to respond to rucaparib

  2014cited by this paper
• BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different

  2014influential reference
• Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

  2014cited by this paper
• Characterization of ovarian cancer long-term responders on olaparib.

  2014cited by this paper
• Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

  2014cited by this paper
• ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.

  2014cited by this paper
• Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition

  2014cited by this paper
• SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).

  2014cited by this paper
• Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

  2013cited by this paper
• PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis.

  2013cited by this paper
• Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance

  2013cited by this paper
• The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells

  2013cited by this paper
• Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation.

  2013cited by this paper
• Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation

  2013cited by this paper
• Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: A randomized, double-blind phase II study.

  2013cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: An open-label phase II study.

  2013cited by this paper
• The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies

  2013cited by this paper
• Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor

  2013cited by this paper
• The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

  2013cited by this paper
• BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

  2013cited by this paper
• Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

  2013cited by this paper
• ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.

  2013cited by this paper
• Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

  2013cited by this paper
• Mechanisms of resistance to therapies targeting BRCA-mutant cancers

  2013cited by this paper
• Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

  2012cited by this paper
• Structural Basis for DNA Damage–Dependent Poly(ADP-ribosyl)ation by Human PARP-1

  2012cited by this paper
• Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.

  2012cited by this paper
• New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs

  2012cited by this paper
• Quantitative proteomics profiling of the poly(ADP-ribose)-related response to genotoxic stress

  2012cited by this paper
• Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.

  2012cited by this paper
• Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro

  2012cited by this paper
• DNA repair dysregulation from cancer driver to therapeutic target

  2012influential reference
• ADP-ribosylation of proteins. Enzymology and biological significance.

  2012cited by this paper
• Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53

  2012cited by this paper
• A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

  2012cited by this paper
• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

  2012cited by this paper
• Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.

  2012cited by this paper
• Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome

  2012cited by this paper
• On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1.

  2012cited by this paper
• PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

  2012cited by this paper
• Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1.

  2012cited by this paper
• The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art.

  2012cited by this paper
• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  2012cited by this paper
• The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease.

  2012cited by this paper
• Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

  2012cited by this paper
• Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors

  2012cited by this paper
• Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.

  2012cited by this paper
• PARPs and the DNA damage response.

  2012cited by this paper
• Towards a structural understanding of PARP1 activation and related signalling ADP-ribosyl-transferases.

  2012cited by this paper
• Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells

  2012cited by this paper
• PARP-3 and APLF function together to accelerate nonhomologous end-joining.

  2011cited by this paper
• Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

  2011cited by this paper
• BRCA1 and BRCA2: different roles in a common pathway of genome protection

  2011cited by this paper
• Checkpoint Signaling, Base Excision Repair, and PARP Promote Survival of Colon Cancer Cells Treated with 5-Fluorodeoxyuridine but Not 5-Fluorouracil

  2011cited by this paper
• Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

  2011cited by this paper
• Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

  2011cited by this paper
• Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.

  2011cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION

  2011cited by this paper
• Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

  2011cited by this paper
• Poly(ADP-ribose) regulates stress responses and microRNA activity in the cytoplasm.

  2011cited by this paper
• Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells

  2011cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.

  2011cited by this paper
• Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes*

  2011cited by this paper
• Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer

  2011cited by this paper
• A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).

  2011cited by this paper
• Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression

  2011cited by this paper
• Poly(ADP‐Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

  2011cited by this paper
• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  2011cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

  2011influential reference
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

  2011cited by this paper
• The USP1/UAF1 Complex Promotes Double-Strand Break Repair through Homologous Recombination

  2011cited by this paper
• Competition between PARP-1 and Ku70 control the decision between high-fidelity and mutagenic DNA repair.

  2011cited by this paper
• The DNA damage response: making it safe to play with knives.

  2010cited by this paper
• PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors

  2010cited by this paper
• 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

  2010cited by this paper
• The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets.

  2010cited by this paper
• 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  2010cited by this paper
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010influential reference

• Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment

  2026cites this paper
• Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer.

  2026cites this paper
• Prevalence of breast cancer in ovarian cancer patients and its impact on patient survival: An analysis of the surveillance, epidemiology, and end results data

  2025cites this paper
• [18F]FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer

  2025cites this paper
• Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase Inhibitors

  2025influential citation
• Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial

  2025cites this paper
• Targeting CDK9 With Harmine Induces Homologous Recombination Deficiency and Synergizes With PARP Inhibitors in Ovarian Cancer

  2025cites this paper
• Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment

  2024cites this paper
• Combating tumor PARP inhibitor resistance: Combination treatments, nanotechnology, and other potential strategies.

  2024cites this paper
• Targeting the Cdc2‐like kinase 2 for overcoming platinum resistance in ovarian cancer

  2024cites this paper
• Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis

  2024cites this paper
• New insights into the dule roles CDK12 in human cancers: Mechanisms and interventions for cancer therapy

  2024cites this paper
• Olaparib Enhances the Efficacy of Third‐Generation Oncolytic Adenoviruses Against Glioblastoma by Modulating DNA Damage Response and p66shc‐Induced Apoptosis

  2024cites this paper
• Mono-ADP-ribosylation, a MARylationmultifaced modification of protein, DNA and RNA: characterizations, functions and mechanisms

  2024cites this paper
• ADP-ribosylation, a multifaceted modification: functions and mechanisms in aging and aging-related diseases.

  2024cites this paper
• Radiosensitization effect of quinoline-indole-schiff base derivative 10E on non-small cell lung cancer cells in vitro and in tumor xenografts

  2024cites this paper
• FANCI Inhibition Induces PARP1 Redistribution to Enhance the Efficacy of PARP Inhibitors in Breast Cancer.

  2024cites this paper
• Isoxazole compounds: Unveiling the synthetic strategy, in-silico SAR & toxicity studies and future perspective as PARP inhibitor in cancer therapy.

  2024cites this paper
• Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer

  2024cites this paper
• Nucleolar Localization of the RNA Helicase DDX21 Predicts Survival Outcomes in Gynecologic Cancers

  2024cites this paper
• PARP inhibitor combinations with high-dose vitamin C in the treatment of Ewing sarcoma: two case reports and mechanistic overview

  2023cites this paper
• Artificial intelligence-based recognition for variant pathogenicity of BRCA1 using AlphaFold2-predicted structures

  2023cites this paper
• BET proteins: Biological functions and therapeutic interventions.

  2023cites this paper
• Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status

  2023cites this paper
• Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer

  2023cites this paper
• A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations

  2023cites this paper
• Novel Cellular Functions of ATR for Therapeutic Targeting: Embryogenesis to Tumorigenesis

  2023cites this paper
• Copper-Mediated Radiobromination of (Hetero)Aryl Boronic Pinacol Esters.

  2023cites this paper
• Characterizing morphologic subtypes of high-grade serous ovarian cancer by CT: a retrospective cohort study

  2023cites this paper
• In Silico Investigation of the Molecular Mechanism of PARP1 Inhibition for the Treatment of BRCA-Deficient Cancers

  2023cites this paper
• Unraveling the allosteric inhibition mechanism of PARP-1 CAT and the D766/770A mutation effects via Gaussian accelerated molecular dynamics and Markov state model

  2023cites this paper
• Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING‐dependent therapy‐induced senescence and provides “one‐two punch” opportunity with anti‐PD‐L1 therapy in colorectal cancer

  2023cites this paper
• Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy

  2023cites this paper
• Anti-tumour and radiosensitising effects of PARP inhibitor on cervical cancer xenografts

  2023cites this paper
• Targeted therapies in ovarian cancer: where we stand and where we are heading

  2023influential citation
• A Comprehensive Review on Current Treatments and Challenges Involved in the Treatment of Ovarian Cancer.

  2023cites this paper
• Ovarian High-grade Serous Carcinoma with Transitional-like (SET) Morphology: A Homologous Recombination-deficient Tumor.

  2023cites this paper
• CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer

  2022cites this paper
• Tumor Suppressive Role of the PRELP Gene in Ovarian Clear Cell Carcinoma

  2022cites this paper
• PARP1 controls the transcription of CD24 by ADP-ribosylating the RNA helicase DDX5 in pancreatic cancer.

  2022cites this paper
• Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma

  2022cites this paper
• DNA Damage Repair in Brain Tumor Immunotherapy

  2022cites this paper
• Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy.

  2022cites this paper
• Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside.

  2022cites this paper
• PARP Inhibitor for Ovarian Cancer Therapy

  2022cites this paper
• Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges

  2022cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib

  2022cites this paper
• Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives

  2022cites this paper
• The expanding universe of PARP1-mediated molecular and therapeutic mechanisms.

  2022cites this paper
• Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials

  2022cites this paper
• Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors

  2022cites this paper
• SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers

  2022cites this paper
• Deep Learning-Based Multi-Omics Integration Robustly Predicts Relapse in Prostate Cancer

  2022cites this paper
• STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

  2022cites this paper
• Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer

  2022cites this paper
• Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy.

  2022cites this paper
• Combinatorial Treatment with Poly(ADP-ribose) Polymerase-1 Inhibitors and Cisplatin Attenuates Cervical Cancer Growth Through Fos-Driven Changes in Gene Expression.

  2022cites this paper
• Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis

  2022cites this paper
• Epithelial tumor compartment- and adjacent stromal compartment-specific expression of PARP1 in different anatomical sites in patients with HGSOC

  2022cites this paper
• PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer

  2021cites this paper
• Combining PD-1/PD-L1 inhibitor and PARP inhibitor: a new perspective on the treatment of triple negative breast cancer

  2021cites this paper
• Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysis

  2021cites this paper
• Health-Related Quality of Life in PARP-Inhibitor Olaparib Maintenance in Ovarian Cancer Patients: Real World Data and Experience of a Single-Center in China

  2021cites this paper
• PARP inhibitors in various cancers

  2021cites this paper
• PARP Inhibitors and Haematological Malignancies—Friend or Foe?

  2021cites this paper
• PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword

  2021cites this paper
• Poly(ADP)-Ribosylation Inhibition: A Promising Approach for Clear Cell Renal Cell Carcinoma Therapy

  2021cites this paper
• VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases

  2021cites this paper
• Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines

  2021cites this paper
• Overview of Olaparib as a treatment option for metastatic castration-resistant prostate cancer

  2021cites this paper
• Real-world hematological adverse events in Chinese patients with advanced ovarian cancer treated with an individualized starting dose of niraparib

  2021cites this paper
• Hacking Pancreatic Cancer: Present and Future of Personalized Medicine

  2021cites this paper
• Enhancing the sensitivity of ovarian cancer cells to olaparib via microRNA-20b-mediated cyclin D1 targeting

  2021cites this paper
• Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance

  2021cites this paper
• Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer

  2021cites this paper
• Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know

  2021cites this paper
• CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors

  2021cites this paper
• PARP1-Inhibition Sensitizes Cervical Cancer Cell Lines for Chemoradiation and Thermoradiation

  2021cites this paper
• The fellowship of the RING: BRCA1, its partner BARD1 and their liaison in DNA repair and cancer.

  2021cites this paper
• Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer.

  2020cites this paper
• Designer Self‐Assembling Peptide Hydrogels to Engineer 3D Cell Microenvironments for Cell Constructs Formation and Precise Oncology Remodeling in Ovarian Cancer

  2020cites this paper
• CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.

  2020cites this paper
• Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy

  2020cites this paper
• CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer

  2020cites this paper
• Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer

  2020influential citation
• Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity

  2020cites this paper
• Immune Therapy Opportunities in Ovarian Cancer.

  2020cites this paper
• CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

  2020cites this paper
• The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review

  2020cites this paper
• Therapeutic applications of PARP inhibitors in ovarian cancer.

  2020cites this paper
• Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging.

  2020cites this paper
• A Phase I/II Study of Veliparib (ABT-888) with Radiation and Temozolomide in Newly Diagnosed Diffuse Pontine Glioma: A Pediatric Brain Tumor Consortium Study.

  2020cites this paper
• Targeting cervical cancer: Is there a role for poly (ADP‐ribose) polymerase inhibition?

  2020cites this paper
• PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications

  2020cites this paper
• Non-Surgical Cancer Risk Reduction in BRCA1 Mutation Carriers: Disabling the Remote Control

  2020cites this paper
• BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

  2020cites this paper
• Current status of cancer immunotherapy for gynecologic malignancies.

  2020cites this paper
• Characterization of a RAD51C-Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development

  2020cites this paper
• Phthalazinone Scaffold:Emerging Tool in the Development of Target Based Novel Anticancer Agents.

  2020cites this paper
• RAD51-Mediated DNA Homologous Recombination Is Independent of PTEN Mutational Status

  2020cites this paper